Abingworth Clinical Co-Development Fund 2 LP is a venture capital fund based in London, United Kingdom. According to its most recent Form D, filed Dec 3, 2020, it has sold $207,480,000 of interests to 22 investors since its first sale in Nov 2020. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Abingworth LLP; Abingworth Clinical Co-Development Fund 2 GP LP.
- Total raised
- $207,480,000Cumulative sales reported on Form D
- Investors
- 22
- First sale
- Nov 19, 2020
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Abingworth LLP; Abingworth Clinical Co-Development Fund 2 GP LP
- Latest Form D
- Dec 3, 2020
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Abingworth Clinical Co-Development Fund 2 LP
What is the minimum investment for Abingworth Clinical Co-Development Fund 2 LP?
Abingworth Clinical Co-Development Fund 2 LP's latest Form D, filed Dec 3, 2020, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Abingworth Clinical Co-Development Fund 2 LP?
Abingworth Clinical Co-Development Fund 2 LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Abingworth Clinical Co-Development Fund 2 LP raised?
Abingworth Clinical Co-Development Fund 2 LP reports $207,480,000 sold from 22 investors on its Form D filed Dec 3, 2020. This is cumulative sales since the offering began, not current assets or performance.
Where is Abingworth Clinical Co-Development Fund 2 LP based?
Abingworth Clinical Co-Development Fund 2 LP is based in London, United Kingdom.
When did Abingworth Clinical Co-Development Fund 2 LP launch?
Abingworth Clinical Co-Development Fund 2 LP reports its first sale in Nov 2020.
Size compared with every venture capital fund
Raised more than 100% of the 43 venture capital funds based in United Kingdom, and more than 99% of all 14,876 that report sales.